BG-12 – update

I had written about new MS drug discoveries last year in September ( ) where I briefly mentioned Biogen Idec’s BG-12 oral drug (among many others: ) for MS.

It now seems that the drug showed promising MRI results in MS patients with regards to being able to reduce inflammation and its potential neuroprotective abilities. From the Medical News Today article (Dec 8th):

BG-12 has been shown to activate the Nrf2 transcriptional pathway, which pre-clinical studies have shown defends against oxidative-stress induced neuronal death, protects the blood-brain barrier and supports maintenance of myelin integrity in the central nervous system. Central nervous system inflammation and damage may trigger the symptoms common in RRMS such as fatigue,┬ácognitive deterioration and physical disability. Because of BG-12’s unique effect on the Nrf2 pathway and its oral delivery, BG-12 is also being considered for future MS combination therapy studies.”

I must say, there are interesting discoveries every day : )

hope is last to die! ; )


Cannabis & MS – more confirmation

An article I saw last week (Medical News Today Dec. 4th) confirms the claims there have been around about the effect of Cannabis on MS patients..

It is highlighted that Cannabis reduces spasticity in MS patients: “the therapeutic potential of cannabinoids in MS is comprehensive and should be given considerable attention“.

you can follow the ‘Medical News Link’ to the right for a bit more info ;)

Cladribine news – timeline

Today I read that Cladribine has not been granted a go ahead by the FDA in the US…so I thought I’d give a look at the process of my report on the drug from when it was first announced together with other potential future treatments last year. And this is how it started…

First in Sept 2008, potential future great drug treatments for MS were announced:


Then again in April the studies & benefits of that same drug were connected to cancer:


And in July Cladribine was being announced as being available soon in Europe as the (potentially) first oral disease modifying drug available to people with MS:


Then more promising clinical trial results where reported in July:


And brief updates on the process of the drug were then given in October:


And finally, as of December 1st 2009 the drug has not (fortunately or unfortunately? who knows..) been approved by the FDA:

so… it is yet to be seen what will happen with this ‘potentially great first oral treatment for MS’